| Greece |
| Hospital base case |
12 117 237
|
0.5
|
— |
| Change from base case |
| Price level of branded product (-10% of base case) starting in cycle 2 |
14 486 246 |
0.60 |
19.6 |
| Price level of branded product (+10% of base case) |
— |
— |
— |
| Price levels of generics/biosimilars (-10% of base case) |
14 639 458 |
0.60 |
20.8 |
| Price levels of generics/biosimilars (+10% of base case) |
— |
— |
— |
| Increased generics/biosimilars uptake by additional 10% of base case for 3 cycles |
15 606 987 |
0.64 |
28.8 |
| Delay of generics/biosimilars entrance by 2 cycles |
9 406 386 |
0.39 |
-22.4 |
| Retail base case |
31 531 951
|
1.30
|
— |
| Change from base case |
| Price level of branded product (-10% of base case) starting in cycle 2 |
31 531 951 |
1.30 |
0 |
| Price level of branded product (+10% of base case) |
— |
— |
— |
| Price levels of generics/biosimilars (-10% of base case) |
37 746 891 |
1.56 |
19.7 |
| Price levels of generics/biosimilars (+10% of base case) |
— |
— |
— |
| Increased generics/biosimilars uptake by additional 10 of base case for 3 cycles |
31 531 951 |
1.30 |
0 |
| Delay of generics/biosimilars entrance by 2 cycles |
31 531 951 |
1.30 |
0 |
| The Netherlands |
| Hospital base case |
192 279 380
|
3.37
|
— |
| Change from base case |
| Price level of branded product (-10% of base case) |
202 077 027 |
3.55 |
5.1 |
| Price level of branded product (+10% of base case) |
182 481 733 |
3.20 |
-5.1 |
| Price levels of generics/biosimilars (-10% of base case) |
209 885 016 |
3.68 |
9.2 |
| Price levels of generics/biosimilars (+10% of base case) |
172 294 991 |
3.02 |
-10.4 |
| Increased generics/biosimilars uptake by additional 10% of base case for 3 cycles |
197 525 697 |
3.47 |
2.7 |
| Delay of generics/biosimilars entrance by 2 cycles |
181 806 923 |
3.19 |
-5.4 |
| Retail base case |
137 391 231
|
2.41
|
— |
| Change from base case |
| Price level of branded product (-10% of base case) |
143 759 494 |
2.52 |
4.6 |
| Price level of branded product (+10% of base case) |
131 022 968 |
2.30 |
-4.6 |
| Price levels of generics/biosimilars (-10% of base case) |
145 356 908 |
2.55 |
5.8 |
| Price levels of generics/biosimilars (+10% of base case) |
124 123 342 |
2.18 |
-9.7 |
| Increased generics/biosimilars uptake by additional 10% of base case for 3 cycles |
141 280 441 |
2.48 |
2.8 |
| Delay of generics/biosimilars entrance by 2 cycles |
127 741 211 |
2.24 |
-7.0 |
| Norway |
| Hospital base case |
36 630 644
|
1.83
|
— |
| Change from base case |
| Price levels of branded and generics/biosimilars (-10% of base case) |
44 593 828 |
2.23 |
21.7 |
| Price levels of branded and generics/biosimilars (+10% of base case) |
28 667 461 |
1.43 |
-21.7 |
| Increased generics/biosimilars uptake by additional 10% of base case for 3 cycles |
— |
— |
— |
| Delay of generics/biosimilars entrance by 2 cycles – branded price remains at max price for 2 cycles |
25 622 614 |
1.28 |
-30.1 |
| Retail base case |
31 431 583
|
1.57
|
— |
| Change from base case |
| Price levels of branded and generics/biosimilars (-10% of base case) |
37 138 772 |
1.86 |
18.2 |
| Price levels of branded and generics/biosimilars (+10% of base case) |
25 724 395 |
1.29 |
-15.4 |
| Increased generics/biosimilars uptake by additional 10% of base case for 3 cycles |
— |
— |
— |
| Delay of generics/biosimilars entrance by 2 cycles – branded price remains at max price for 2 cycles |
20 414 188 |
1.02 |
-42.8 |
| Sweden |
| Hospital base case |
31 301 981
|
0.70
|
— |
| Change from base case |
| Price level of branded product (-10% of base case) |
31 539 414 |
0.71 |
0.8 |
| Price level of branded product (+10% of base case) |
31 064 548 |
0.70 |
-0.8 |
| Price levels of generics/biosimilars (-10% of base case) |
35 960 247 |
0.81 |
14.9 |
| Price levels of generics/biosimilars (+10% of base case) |
26 643 715 |
0.60 |
-14.9 |
| Increased generics/biosimilars uptake by additional 10 of base case for 3 cycles |
39 920 917 |
0.90 |
27.5 |
| Delay of generics/biosimilars entrance by 2 cycles |
18 836 744 |
0.47 |
-60.2 |
| Retail base case |
175 718 837
|
3.95
|
— |
| Change from base case |
| Price level of branded product (-10% of base case) |
176 947 322 |
3.97 |
0.7 |
| Price level of branded product (+10% of base case) |
175 718 837 |
3.95 |
0 |
| Price levels of generics/biosimilars (-10% of base case) |
193 659 299 |
4.35 |
10.2 |
| Price levels of generics/biosimilars (+10% of base case) |
155 989 774 |
3.50 |
-11.2 |
| Increased generics/biosimilars uptake by additional 10% of base case for 3 cycles |
222 722 033 |
5.00 |
26.7 |
| Delay of generics/biosimilars entrance by 2 cycles |
88 570 244 |
2.21 |
-50.4 |